Scientific Advisors

APIM Therapeutics's Advisory Board comprises the following members.

Professor Justin Stebbing, M.D., M.A., FRCP, FRC Path, Ph.D., Imperial College and Imperial College Healthcare NHS Trust (UK).

Dr. Stebbing is a Professor of Cancer Medicine and Oncology, and a Consultant Oncologist at Imperial College and Imperial College Healthcare NHS Trust. He is a Fellow of the Royal College of Pathologists, the Royal College of Physicians and the American Board of Internal Medicine. Dr. Stebbing sits on the advisory boards of several biotech companies and international cancer committees, and chairs the World Vaccine Congress and the Irish Cancer Society oversight committee. He is on the editorial board of a number of world leading general medical and cancer journals, such as the Journal of Clinical Oncology and the Lancet Oncology, and is the Editor-in-Chief of Oncogene (Nature Publishing Group's cancer journal). Dr. Stebbing was awarded the Silvia Lawler prize in 2015.

Prof. Stebbing trained in medicine at Trinity College Oxford, obtaining a triple first class degree. After completing his residency at The Johns Hopkins Hospital in the United States, he returned to London to continue his training in oncology at The Royal Marsden and St. Bartholomew's Hospitals. Funded by the Medical Research Council, he undertook a Ph.D. investigating the interplay between cancer and the immune system. Dr. Stebbing has published over 600 peer-reviewed papers, the majority of which as first or last author, in journals such as The Lancet, The New England Journal of Medicine, Blood, Journal of Clinical Oncology and Annals of Internal Medicine, and has authored more than 100 book chapters. His work primarily addresses early and late stage trials of new drugs, and mechanisms of disease, including relapse and resistance mechanisms, and prognostic indicators.

Leads to Development

The Company enjoys the strong support of Leads to Development, a dedicated drug development and regulatory consultancy having two of its Directors, Vincent Dubois, Ph.D. and Jonathan Kearsey, Ph.D. advising the company on various preclinical and clinical aspects.